HK1252050A1 - 嘧啶组成物、其超纯组成物及盐类、制造彼之方法、及使用彼於治疗组织胺h4受体(h4)仲介之疾病与病情之方法 - Google Patents

嘧啶组成物、其超纯组成物及盐类、制造彼之方法、及使用彼於治疗组织胺h4受体(h4)仲介之疾病与病情之方法 Download PDF

Info

Publication number
HK1252050A1
HK1252050A1 HK18111382.3A HK18111382A HK1252050A1 HK 1252050 A1 HK1252050 A1 HK 1252050A1 HK 18111382 A HK18111382 A HK 18111382A HK 1252050 A1 HK1252050 A1 HK 1252050A1
Authority
HK
Hong Kong
Prior art keywords
same
methods
compositions
ultra
making
Prior art date
Application number
HK18111382.3A
Other languages
English (en)
Chinese (zh)
Inventor
Zhijian Zhu
Helen BARKER
Michael Yeadon
Wai Liu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1252050A1 publication Critical patent/HK1252050A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18111382.3A 2015-10-26 2016-10-25 嘧啶组成物、其超纯组成物及盐类、制造彼之方法、及使用彼於治疗组织胺h4受体(h4)仲介之疾病与病情之方法 HK1252050A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562246482P 2015-10-26 2015-10-26
US62/246,482 2015-10-26
US201662329091P 2016-04-28 2016-04-28
US62/329,091 2016-04-28
US201662359066P 2016-07-06 2016-07-06
US62/359,066 2016-07-06

Publications (1)

Publication Number Publication Date
HK1252050A1 true HK1252050A1 (zh) 2019-05-10

Family

ID=57200025

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111382.3A HK1252050A1 (zh) 2015-10-26 2016-10-25 嘧啶组成物、其超纯组成物及盐类、制造彼之方法、及使用彼於治疗组织胺h4受体(h4)仲介之疾病与病情之方法

Country Status (21)

Country Link
US (2) US20170158671A1 (cg-RX-API-DMAC7.html)
EP (1) EP3368528A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018531288A (cg-RX-API-DMAC7.html)
KR (1) KR20180067683A (cg-RX-API-DMAC7.html)
CN (1) CN108602801A (cg-RX-API-DMAC7.html)
AU (2) AU2016344627B9 (cg-RX-API-DMAC7.html)
BR (1) BR112018007765A2 (cg-RX-API-DMAC7.html)
CA (1) CA3001636A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018001092A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018004323A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP18038867A (cg-RX-API-DMAC7.html)
HK (1) HK1252050A1 (cg-RX-API-DMAC7.html)
IL (1) IL258813A (cg-RX-API-DMAC7.html)
MX (1) MX2018005140A (cg-RX-API-DMAC7.html)
PE (1) PE20181364A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018500822A1 (cg-RX-API-DMAC7.html)
RU (1) RU2018119104A (cg-RX-API-DMAC7.html)
SG (1) SG11201802676QA (cg-RX-API-DMAC7.html)
TW (1) TW201729810A (cg-RX-API-DMAC7.html)
WO (1) WO2017072131A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201802183B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
AU2018349284B2 (en) * 2017-10-09 2023-11-16 428 Pharma BV. New salt and solid state forms of escitalopram
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗il31抗体
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
AU2003272285A1 (en) 2002-09-06 2004-03-29 Janssen Pharmaceutica, N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
KR101235116B1 (ko) * 2005-10-17 2013-02-20 에스케이케미칼주식회사 광학활성 암로디핀 겐티세이트 염의 제조방법
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JP2008127359A (ja) * 2006-11-22 2008-06-05 Kowa Co アトピー性皮膚炎の予防及び/又は治療剤
HUE039713T2 (hu) * 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére

Also Published As

Publication number Publication date
JP2018531288A (ja) 2018-10-25
US20170158671A1 (en) 2017-06-08
AU2016344627A1 (en) 2018-05-10
TW201729810A (zh) 2017-09-01
AU2020200840A1 (en) 2020-02-27
CL2018001092A1 (es) 2018-08-10
PH12018500822A1 (en) 2018-10-01
PE20181364A1 (es) 2018-08-27
ZA201802183B (en) 2019-02-27
RU2018119104A (ru) 2019-11-28
AU2016344627B9 (en) 2019-11-28
RU2018119104A3 (cg-RX-API-DMAC7.html) 2020-02-19
CA3001636A1 (en) 2017-05-04
KR20180067683A (ko) 2018-06-20
AU2016344627B2 (en) 2019-11-07
EP3368528A1 (en) 2018-09-05
WO2017072131A1 (en) 2017-05-04
CO2018004323A2 (es) 2018-07-19
CN108602801A (zh) 2018-09-28
MX2018005140A (es) 2018-05-07
US20190135787A1 (en) 2019-05-09
ECSP18038867A (es) 2018-05-31
BR112018007765A2 (pt) 2018-10-23
SG11201802676QA (en) 2018-05-30
IL258813A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
PH12018500822A1 (en) Pyrimidine compositions, ultra-pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine h4 receptor (h4) mediated diseases and conditions
PH12016500938A1 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
SA518400333B1 (ar) شكل متعدد الأشكال من n- {6-(2-هيدروكسي بروبان-2-يل) -2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد
HK1246667A1 (zh) 作为jak抑制剂的2-(吡唑并吡啶-3-基)嘧啶衍生物
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
EA201890001A1 (ru) Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk)
MX381053B (es) Formas cristalinas de las sales del compuesto 5-(((1r,1as,6br)-1-(6-(trifluorometil)-1h-benzo[d]imidazol-2-il)-1a,6b-dihidro-1h-ciclopropa [b] benzofuran-5-il) oxi)-3,4-dihidro-1,8-naftiridin-2(1h)-ona, sus métodos de preparación sus usos de las mismas.
MY196185A (en) Salts of a Pim Kinase Inhibitor
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
HK1252245A1 (zh) 用於治疗癌症的核苷酸
MX2016005174A (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
WO2018156895A8 (en) Inhibitors of bruton's tyrosine kinase
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
AR106577A1 (es) Composiciones de pirimidina, composiciones ultrapuras y sus sales, sus métodos de preparación y sus métodos de uso para el tratamiento de enfermedades y condiciones mediadas por el receptor de histamina h4 (h4)
HK1248601A1 (zh) 作為激酶抑制劑的嘧啶衍生物及其治療應用
HK1209575A2 (en) Isoquinolinone derivatives as nk3 antagonists